The Department of Lymphoma and Myeloma (R.J.J., D.G., C.C.B., I.K., R.Z.O.) and the Department of Experimental Therapeutics (R.Z.O.), The University of Texas MD Anderson Cancer Center, Houston, Texas; Lipoprotein Metabolism Section, Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (A.T.R.); and Oncology, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium (T.B., V.V.)

The Department of Lymphoma and Myeloma (R.J.J., D.G., C.C.B., I.K., R.Z.O.) and the Department of Experimental Therapeutics (R.Z.O.), The University of Texas MD Anderson Cancer Center, Houston, Texas; Lipoprotein Metabolism Section, Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (A.T.R.); and Oncology, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium (T.B., V.V.)

The Department of Lymphoma and Myeloma (R.J.J., D.G., C.C.B., I.K., R.Z.O.) and the Department of Experimental Therapeutics (R.Z.O.), The University of Texas MD Anderson Cancer Center, Houston, Texas; Lipoprotein Metabolism Section, Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (A.T.R.); and Oncology, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium (T.B., V.V.)

The Department of Lymphoma and Myeloma (R.J.J., D.G., C.C.B., I.K., R.Z.O.) and the Department of Experimental Therapeutics (R.Z.O.), The University of Texas MD Anderson Cancer Center, Houston, Texas; Lipoprotein Metabolism Section, Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (A.T.R.); and Oncology, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium (T.B., V.V.)

The Department of Lymphoma and Myeloma (R.J.J., D.G., C.C.B., I.K., R.Z.O.) and the Department of Experimental Therapeutics (R.Z.O.), The University of Texas MD Anderson Cancer Center, Houston, Texas; Lipoprotein Metabolism Section, Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (A.T.R.); and Oncology, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium (T.B., V.V.)

The Department of Lymphoma and Myeloma (R.J.J., D.G., C.C.B., I.K., R.Z.O.) and the Department of Experimental Therapeutics (R.Z.O.), The University of Texas MD Anderson Cancer Center, Houston, Texas; Lipoprotein Metabolism Section, Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (A.T.R.); and Oncology, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium (T.B., V.V.)

The Department of Lymphoma and Myeloma (R.J.J., D.G., C.C.B., I.K., R.Z.O.) and the Department of Experimental Therapeutics (R.Z.O.), The University of Texas MD Anderson Cancer Center, Houston, Texas; Lipoprotein Metabolism Section, Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (A.T.R.); and Oncology, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium (T.B., V.V.)

The Department of Lymphoma and Myeloma (R.J.J., D.G., C.C.B., I.K., R.Z.O.) and the Department of Experimental Therapeutics (R.Z.O.), The University of Texas MD Anderson Cancer Center, Houston, Texas; Lipoprotein Metabolism Section, Cardiopulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland (A.T.R.); and Oncology, Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium (T.B., V.V.)